A Phase 2 randomized clinical trial demonstrates that TSND-201, a novel neuroplastogen, significantly reduces PTSD symptoms and functional disability without intensive psychotherapy, offering a potentially rapid and durable treatment option for patients with chronic posttraumatic stress disorder.